



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: **R406 (free base)**  
 产品别名: **R406 free base**

生物活性:														
<b>Description</b>	<p>R406 free base is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to FIt3. IC50 value: 41 nM [1] Target: Syk in vitro: R406 is a potent inhibitor of immunoglobulin E (IgE)- and IgG-mediated activation of Fc receptor signaling. R406 inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNF<math>\alpha</math>, IL-8, and GM-CSF. R406 inhibits phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells. R406 binds to the ATP binding pocket of Syk and inhibits its kinase activity as an ATP-competitive inhibitor with Ki of 30 nM. R406 blocks Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and Bcr-mediated activation of B lymphocytes [1]. R406 significantly induces chronic lymphocytic leukemia (CLL) cell apoptosis in nurselike cells cocultures and blocks CCL3 and CCL4 secretion by CLL cells in response to B-cell antigen receptor (Bcr) triggering [2]. R406 is a potent inhibitor of platelet signaling and functions initiated by Fc<math>\gamma</math>RIIA cross-linking by specific antibodies or by sera from HIT patients [3]. in vivo: R406 reduces cutaneous reverse passive Arthus reaction by approximately 86% at 5 mg/kg in prophylactic treated mice. R406 also shows efficacy in inhibiting paw inflammation in antibody-induced arthritis mouse models [1]. R406 does not adversely affect macrophage or neutrophil function in innate immune responses and has minimal functional immunotoxicity notwithstanding its lymphocytopenic effect [4].</p>													
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b>  <b>DMSO : <math>\geq</math> 10 mg/mL (21.26 mM)</b>            * "<math>\geq</math>" means soluble, but saturation unknown.</p>													
	<b>Preparing</b>	<table border="1"> <thead> <tr> <th style="text-align: center;">Solvent Concentration</th> <th style="text-align: center;">Mass</th> <th style="text-align: center;">1 mg</th> <th style="text-align: center;">5 mg</th> <th style="text-align: center;">10 mg</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1 mM</td> <td></td> <td style="text-align: center;">2.1256 mL</td> <td style="text-align: center;">10.6281 mL</td> <td style="text-align: center;">21.2562 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM		2.1256 mL	10.6281 mL	21.2562 mL		
	Solvent Concentration	Mass	1 mg	5 mg	10 mg									
	1 mM		2.1256 mL	10.6281 mL	21.2562 mL									
<b>Stock Solutions</b>	<table border="1"> <tbody> <tr> <td style="text-align: center;">5 mM</td> <td style="text-align: center;">0.4251 mL</td> <td style="text-align: center;">2.1256 mL</td> <td style="text-align: center;">4.2512 mL</td> </tr> <tr> <td style="text-align: center;">10 mM</td> <td style="text-align: center;">0.2126 mL</td> <td style="text-align: center;">1.0628 mL</td> <td style="text-align: center;">2.1256 mL</td> </tr> </tbody> </table>	5 mM	0.4251 mL	2.1256 mL	4.2512 mL	10 mM	0.2126 mL	1.0628 mL	2.1256 mL					
5 mM	0.4251 mL	2.1256 mL	4.2512 mL											
10 mM	0.2126 mL	1.0628 mL	2.1256 mL											
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。            储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> <p><b>In Vivo:</b>            请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:            ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: <math>\geq</math> 0.5 mg/mL (1.06 mM); Clear solution</p> <p>此方案可获得 <math>\geq</math> 0.5 mg/mL (1.06 mM, 饱和度未知) 的澄清溶液。</p>														



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 5.0 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中, 混合均匀向上述体系中加入 50 <math>\mu</math>L Tween-80, 混合均匀; 然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂: 10% DMSO <math>\rightarrow</math> 90% corn oil</p> <p>Solubility: <math>\geq</math> 0.5 mg/mL (1.06 mM); Clear solution</p> <p>此方案可获得 <math>\geq</math> 0.5 mg/mL (1.06 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 5.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
<b>References</b>	<p>[1]. Braselmann S, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. <i>J Pharmacol Exp Ther</i>, 2006, 319(3), 998-1008.</p> <p>[2]. Quiroga MP, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. <i>Blood</i>, 2009, 114(5), 1029-1037.</p> <p>[3]. Lhermusier T, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. <i>J Thromb Haemost</i>, 2011, 9(10), 2067-2076.</p> <p>[4]. Zhu Y, et al. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. <i>Toxicol Appl Pharmacol</i>, 2007, 221(3), 268-277.</p>

源叶生物